Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 6/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11247 | 0.86 | KMT2A (0.46) | MAPTKMT2ACES1KCNN4HTT | |
| SCHEMBL2729130 | 0.85 | CES1 (0.46) | MAPTKMT2ACES1KCNN4KIF11 | |
| SCHEMBL28033810 | 0.84 | MAPT (0.47) | MAPTKMT2AKCNN4HTTKIF11 | |
| SCHEMBL20293767 | 0.84 | MAPT (0.47) | MAPTKMT2AKCNN4HTTKIF11 | |
| SCHEMBL18901487 | 0.84 | CES1 (0.44) | MAPTKMT2ACES1KCNN4KIF11 | |
| SCHEMBL23256417 | 0.83 | MAPT (0.46) | MAPTKMT2ACES1KCNN4HTT | |
| SCHEMBL7979097 | 0.83 | PIN1 (0.49) | MAPTCES1KCNN4CHRM2CHRM1 | |
| SCHEMBL7507157 | 0.81 | MAPT (0.44) | MAPTKMT2AKCNN4HTTKIF11 | |
| SCHEMBL2028143 | 0.81 | KCNN4 (0.43) | MAPTKMT2ACES1KCNN4HTT | |
| SCHEMBL10456740 | 0.81 | CES1 (0.59) | MAPTCES1KCNN4CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044107-A1 | Inhibitors of JMJD2C as Anticancer Agents | THE J. DAVID GLADSTONE INSTITUTES | 2017-02-16 | — | — | US | disclosed |
| US-20050124652-A1 | Guanidino compounds | BOYCE RUSTUM (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1458724-A1 | TOTAL SYNTHESIS OF GALANTHAMINE, ANALOGUES AND DERIVATIVES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-09-22 | — | — | EP | disclosed |
| WO-2002102803-A1 | TOTAL SYNTHESIS OF GALANTHAMINE, ANALOGUES AND DERIVATIVES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044107-A1 | Inhibitors of JMJD2C as Anticancer Agents | KDM2A, KDM1B, KDM5C | MAPT 3264/4885KMT2A 24/4885CES1 3122/4885 |
| US-20050124652-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | MAPT 2811/4885KMT2A 3202/4885CES1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.